Genomic and rapid effects of aldosterone: what we know and do not know thus far
- PMID: 27942913
- DOI: 10.1007/s10741-016-9591-2
Genomic and rapid effects of aldosterone: what we know and do not know thus far
Abstract
Aldosterone is the most known mineralocorticoid hormone synthesized by the adrenal cortex. The genomic pathway displayed by aldosterone is attributed to the mineralocorticoid receptor (MR) signaling. Even though the rapid effects displayed by aldosterone are long known, our knowledge regarding the receptor responsible for such event is still poor. It is intense that the debate whether the MR or another receptor-the "unknown receptor"-is the receptor responsible for the rapid effects of aldosterone. Recently, G protein-coupled estrogen receptor-1 (GPER-1) was elegantly shown to mediate some aldosterone-induced rapid effects in several tissues, a fact that strongly places GPER-1 as the unknown receptor. It has also been suggested that angiotensin receptor type 1 (AT1) also participates in the aldosterone-induced rapid effects. Despite this open question, the relevance of the beneficial effects of aldosterone is clear in the kidneys, colon, and CNS as aldosterone controls the important water reabsorption process; on the other hand, detrimental effects displayed by aldosterone have been reported in the cardiovascular system and in the kidneys. In this line, the MR antagonists are well-known drugs that display beneficial effects in patients with heart failure and hypertension; it has been proposed that MR antagonists could also play an important role in vascular disease, obesity, obesity-related hypertension, and metabolic syndrome. Taken altogether, our goal here was to (1) bring a historical perspective of both genomic and rapid effects of aldosterone in several tissues, and the receptors and signaling pathways involved in such processes; and (2) critically address the controversial points within the literature as regarding which receptor participates in the rapid pathway display by aldosterone.
Keywords: Aldosterone; G protein-coupled estrogen receptor-1 (GPER-1); Genomic effects; Mineralocorticoid receptor (MR); Rapid or non-genomic effect.
Similar articles
-
New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.Curr Drug Targets. 2018;19(16):1968-1979. doi: 10.2174/1389450119666180326125926. Curr Drug Targets. 2018. PMID: 29577853 Review.
-
Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation.Am J Physiol Cell Physiol. 2013 Mar;304(6):C532-40. doi: 10.1152/ajpcell.00203.2012. Epub 2013 Jan 2. Am J Physiol Cell Physiol. 2013. PMID: 23283935
-
Expression of functional mineralocorticoid receptor (MR) and G-protein coupled estrogen receptor (GPER) in human T lymphocytes.Steroids. 2023 Dec;200:109327. doi: 10.1016/j.steroids.2023.109327. Epub 2023 Oct 10. Steroids. 2023. PMID: 37827440
-
Aldosterone and mineralocorticoid receptors in the cardiovascular system.Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):393-400. doi: 10.1016/j.pcad.2009.12.003. Prog Cardiovasc Dis. 2010. PMID: 20226957 Review.
-
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor.J Endocrinol. 2017 Jul;234(1):T107-T124. doi: 10.1530/JOE-16-0659. Epub 2017 Mar 27. J Endocrinol. 2017. PMID: 28348113 Review.
Cited by
-
Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy.Ther Adv Chronic Dis. 2023 Jan 16;14:20406223221143233. doi: 10.1177/20406223221143233. eCollection 2023. Ther Adv Chronic Dis. 2023. PMID: 36687666 Free PMC article.
-
Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism.Front Physiol. 2019 Nov 22;10:1434. doi: 10.3389/fphys.2019.01434. eCollection 2019. Front Physiol. 2019. PMID: 31824340 Free PMC article.
-
Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease.J Vet Pharmacol Ther. 2020 May;43(3):243-267. doi: 10.1111/jvp.12848. Epub 2020 Mar 3. J Vet Pharmacol Ther. 2020. PMID: 32128854 Free PMC article. Review.
-
Diabetic Kidney Disease: Challenges, Advances, and Opportunities.Kidney Dis (Basel). 2020 Jul;6(4):215-225. doi: 10.1159/000506634. Epub 2020 Mar 31. Kidney Dis (Basel). 2020. PMID: 32903946 Free PMC article. Review.
-
How New Developments in Pharmacology Receptor Theory Are Changing (Our Understanding of) Hypertension Therapy.Am J Hypertens. 2024 Mar 15;37(4):248-260. doi: 10.1093/ajh/hpad121. Am J Hypertens. 2024. PMID: 38150382 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials